What changed
The Inflation Reduction Act gives Medicare the power to negotiate prices for some high-spending drugs. It also carves out categories, including "a biological product that is derived from human whole blood or plasma. AbbVie's argument is simple. Botox contains human serum albumin (HSA), a protein from donated plasma. The company says albumin is about one-third of the product. Its complaint also says Botox carries about 100,000 times more albumin than its active ingredient, onabotulinumtoxinA, and that the label states it contains albumin, "a derivative of human blood."
The statute does not define "derived," so the judge used the ordinary meaning. Per Health Law Daily, as quoted by Medical Daily, the court found it undisputed that the product cannot be made without HSA. That finding carried the case.
CMS had argued the court had no jurisdiction because the law bars review of drug selection. The judge disagreed. He relied on an August 2026 D.C. Circuit decision in a Teva Pharmaceuticals case that allows courts to review the general legal standards CMS uses. That is the part of this ruling I expect other manufacturers to read closely.
Most industry challenges have lost. The Supreme Court turned away drugmaker appeals on May 18, leaving lower-court dismissals in place. AbbVie's case is different because it targets the plasma exclusion itself, not the price-setting formula.
What it means for practices
Read this as a Medicare-pricing story, not a clinic-pricing story. The ruling blocks one future federal number. It does not change what a patient pays today. It does not change what you bill.
The number that matters to you is the Part B coinsurance. Traditional Medicare generally pays up to 20% of the Medicare-approved amount after the Part B deductible, and that coinsurance moves with the drug's price. A lower negotiated price for Botox, which was set to take effect Jan. 1, 2028, would have pulled that coinsurance down for patients without supplemental coverage. Blocking that price means the coinsurance stays where it is. For a practice, the difference shows up in patient conversations about cost, not in the claim.
Medicare generally does not cover cosmetic procedures. The agency's own guidance flags botulinum toxin injections as services that are sometimes considered cosmetic and may need prior authorization. Medical uses such as chronic migraine, overactive bladder, and muscle spasticity are the covered indications the reporting points to. Your cosmetic patients were never on Medicare's books for this.
What owners can do
Keep scheduling as planned. The document says patients should keep their treatments and talk with their clinician about concerns, and that advice holds for your front desk too.
If a Medicare patient asks whether the ruling lowers their bill, tell them no, not for now. Point them to the State Health Insurance Assistance Program, which offers free, unbiased Medicare counseling.
Check your own Part B billing for any Botox-related Medicare claims against the coinsurance and prior authorization rules in place today. Nothing in the ruling changes those rules.
What we don't know yet
HHS had not said as of Nov. 4 whether it will appeal. An appeal would go to the D.C. Circuit. No appeal had been reported by that date, so the ruling stands for now, but it has not been tested above the trial court.
The document does not say whether the court's reading of "derived" could reach other biologics that contain plasma-derived components. Nobody in the reporting has analyzed that, and it is the question I would watch.
CMS must still publish agreed prices for the other 14 drugs in the round, including Gilead's Biktarvy, by Nov. 30. The ruling does not directly affect them. The 15 selected drugs accounted for about $27 billion in Part B and Part D spending, and about 1.8 million Medicare beneficiaries used them from November 2024 to October 2025, per CMS.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.
